PMID: 9524092Apr 2, 1998Paper

Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma--a report of the Children's Cancer Group

Journal of Neuro-oncology
W P MasonJonathan L Finlay

Abstract

Recurrent intracranial ependymoma is rarely cured by surgery, radiotherapy, and chemotherapy in conventional doses. This study was designed to determine the toxicity, radiographic response rate and outcome following intensive chemotherapy with ThioTEPA, etoposide, carboplatinum and autologous bone marrow rescue (ABMR) for young children with recurrent central nervous system ependymoma. ThioTEPA 300 mg/m2/day (total 900 mg/m2) and etoposide 250 to 500 mg/m2/day (total 750 to 1500 mg/m2) were administered for three consecutive days with or without the addition of carboplatinum 500 mg/m2/day (total 1500 mg/m2) for an additional three consecutive days, and autologous bone marrow was reinfused 72 hours following chemotherapy. Eligibility criteria required adequate renal, hepatic and pulmonary function, and no tumor infiltration of bone marrow. Fifteen children with recurrent intracranial ependymoma, aged 5 months to 12 years (median 22 months), were treated. Five patients died of treatment related toxicities within 62 days of marrow reinfusion. Eight have expired from progressive disease a median of six months post-ABMR, and one has died from unrelated causes. One child remains alive 25 months post-ABMR, following further disease re...Continue Reading

Citations

Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J GrillUNKNOWN French Society of Pediatric Oncology
Aug 5, 2003·Paediatric Drugs·Jacques GrillKalifa Chantal
Oct 31, 2003·Current Treatment Options in Oncology·Timothy J Moynihan
Jan 31, 2006·Neuro-oncology·David S ZieglerUNKNOWN Australian and New Zealand Children's Study Group
Sep 1, 2006·Current Treatment Options in Neurology·Sajeel ChowdharyMarc Chamberlain
May 22, 2009·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Kyu-Won ShimJoong-Uhn Choi
Oct 21, 2009·Journal of Child Neurology·Stergios Zacharoulis, Lucas Moreno
Jul 2, 2009·Cancer·Marc C Chamberlain, Sandra K Johnston
Oct 2, 2007·Journal of Neuro-oncology·Daniel Ka Leung CheukGodfrey Chi Fung Chan
Dec 24, 2011·Interventional Neuroradiology : Journal of Peritherapeutic Neuroradiology, Surgical Procedures and Related Neurosciences·P RajappaJeffrey P Greenfield
Jul 16, 2015·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Tryggve LundarPetter Brandal
May 31, 2017·Cancer Control : Journal of the Moffitt Cancer Center·Sajeel ChowdharyMarc C Chamberlain
May 31, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sridharan GururanganPaul L Martin
Sep 5, 2002·Cancer·Marc C Chamberlain
Oct 31, 2002·Journal of Neurosurgery·Marie-Lise C van Veelen-VincentDominique Renier
Oct 1, 2005·Journal of Neuro-oncology·Thomas E Merchant, Maryam Fouladi
Apr 11, 2009·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Eric BouffetUte Bartels
Mar 13, 2014·Pediatric Blood & Cancer·Reuben AntonyJonathan L Finlay
Mar 20, 1999·Current Opinion in Pediatrics·J B Rubin, M W Kieran
Oct 18, 2002·Expert Review of Anticancer Therapy·Michele Reni, Alba A Brandes
Jun 2, 2009·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·M SangraC Mallucci
Oct 15, 2013·Expert Review of Neurotherapeutics·Ian F PollackHideho Okada
Dec 30, 2009·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Stergios ZacharoulisDidier Frappaz
Apr 15, 2003·Current Neurology and Neuroscience Reports·Marc C Chamberlain
Mar 18, 2004·Neurosurgery Clinics of North America·Aaron S DumontMark E Shaffrey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.